Donepezil in Alzheimer's disease: Eighteen month results from Southampton Memory Clinic

The objective of this study was to assess the efficacy of donepezil in pati ents with mild to moderate Alzheimer's disease (AD) in clinical practice. T his was an open-label study in which patients were referred to an elderly m ental health clinic in Southampton, UK. Eighty patients with mild to modera te AD received 5 mg/day donepezil for the first 4 weeks, after which, if to lerated, the dose was increased to 10 mg/day. Efficacy and safety assessmen ts were carried out every 3 months. Efficacy was assessed by the Alzheimer' s Disease Assessment Scale-cognitive subscale (ADAS-cog), Mini-Mental State Examination (MMSE), Neuropsychiatric Inventory (NPI), Neuropsychiatric Inv entory-carer Distress Scale (NPI-D). Mean improvements from baseline were o bserved at the 3-month assessment on all four efficacy measures. At 3 month s, 39% of patients showed an improvement of at least 4 points on the ADAS-c og, and 37% of patients had improved by 4 points or more on the NPI. In tho se patients who showed improvement and were maintained on donepezil, improv ements were sustained for 18 months on the MMSE and NPI, 15 months on the N PI-D, and for 6 months on the ADAS-cog. Six per cent of patients discontinu ed medication due to adverse events. In a typical clinical practice setting , patients with mild to moderate AD tolerated donepezil well. Clinically me aningful improvements in cognitive function and a reduction in neuropsychia tric symptoms were demonstrated in nearly 40% of patients with associated r eduction in carer distress. Continued benefit was seen for up to 18 months in the selected group of patients who initially responded to treatment. Cop yright (C) 2000 John Wiley & Sons, Ltd.